Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | HTR6 | P50406 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | EGFR | P00533 | 2/20 | 0.31 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.31 |
| ▸ | FADS1 | O60427 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL463751 | 0.82 | TSHR (0.50) | CYP3A4TP53ALDH1A1MAPTIDO1 | |
| SCHEMBL13677416 | 0.82 | HTR6 (0.42) | CYP3A4TP53HTR6ALDH1A1MAPT | |
| SCHEMBL3783747 | 0.82 | TSHR (0.41) | HTR6ALDH1A1MAPTIDO1RAPGEF4 | |
| SCHEMBL12990555 | 0.82 | HTR6 (0.47) | CYP3A4TP53HTR6ALDH1A1MAPT | |
| SCHEMBL10316417 | 0.76 | CYP3A4 (0.55) | CYP3A4TP53ALDH1A1MAPTIDO1 | |
| SCHEMBL21249789 | 0.76 | HTR6 (0.40) | CYP3A4TP53HTR6ALDH1A1TSHR | |
| SCHEMBL3787936 | 0.76 | CYP3A4 (0.48) | CYP3A4TP53HTR6ALDH1A1MAPT | |
| SCHEMBL12991010 | 0.73 | ALDH1A1 (0.60) | CYP3A4HTR6ALDH1A1MAPTRAPGEF4 | |
| SCHEMBL16786088 | 0.73 | RAPGEF4 (0.48) | ALDH1A1MAPTIDO1RAPGEF4LMNA | |
| SCHEMBL25352160 | 0.73 | KDM1A (0.49) | CYP3A4TP53ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | NISCH, BLVRB, BBOX1 | CYP3A4 177/4885TP53 2819/4885HTR6 2438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.